Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks
Launched by YALE UNIVERSITY · Nov 29, 2022
Trial Information
Current as of November 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how THC, the active ingredient in cannabis, affects brain activity during learning. Researchers will use advanced brain imaging techniques called magnetoencephalography (MEG) and electroencephalography (EEG) to see how THC influences the brain's performance, specifically focusing on working memory, which is the ability to hold and manipulate information in your mind.
To be eligible for this study, participants must have used cannabis at least once in the past year but must not use it during the trial. They should be in good physical and mental health and meet several other criteria, such as having a certain level of intelligence and not having certain medical or psychological conditions. Participants will undergo a series of tests and brain scans while being monitored for THC effects. This study is important as it may help us understand the impacts of cannabis on learning and memory, which could have implications for individuals who use cannabis regularly. Please note that the trial is not yet open for enrollment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cannabis use at least once in the past 12 months
- • No cannabis use during the course of the study confirmed with negative urine toxicology at screening and on each test day
- • Good physical and mental health
- Exclusion Criteria:
- • Cannabis naïve individuals
- • Lifetime or current medical, psychiatric or psychosocial disorders or history that is deemed unsuitable for participation in the study per PI discretion.
- • Positive pregnancy test, lactation, or refusal to practice birth control for the duration of the study and for two weeks following completion
- • Major current or recent stressors
- • Positive urine drug test
- • Contraindication for Magnetic Resonance Imaging
- • Treatment with psychotropic medication as per discretion of the PI
- • IQ less than 80
- • Weight exceeding 166kg
- • Diagnosis of major psychotic or manic disorder in first-degree relatives.
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
West Haven, Connecticut, United States
Patients applied
Trial Officials
Jose Cortes-Briones, PhD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials